middle.news
Echo IQ Launches Mayo Clinic Study to Validate Heart Failure AI Ahead of FDA Bid
10:03am on Tuesday 1st of July, 2025 AEST
•
Healthcare
Read Story
Echo IQ Launches Mayo Clinic Study to Validate Heart Failure AI Ahead of FDA Bid
10:03am on Tuesday 1st of July, 2025 AEST
Key Points
Clinical validation study for EchoSolv HF underway with Mayo Clinic Platform
Study uses Mayo Validate to independently assess AI accuracy and bias
Final regulatory hurdle before formal FDA 510(k) submission expected in H2 2025
Mayo Clinic gains rights to use and co-brand EchoSolv HF across 30 hospitals
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Echoiq (ASX:EIQ)
OPEN ARTICLE